conferenceseries.com

Tentative Program

18th Global Summit and Expo on

Vaccines & Vaccination

September 18-19, 2017 Houston, USA

Theme: "A New Era in Vaccines Research & Development"



For Available Speaker Slots

americanvaccaines@conferenceseries.netamericanvaccines@vaccineconference.com

CME Accredited

Accredited cpd Event

15+ Interactive Sessions

10+ Keynote Lectures

Conference Secretariat

2360 Corporate Circle, Suite 400 Henderson, NV 89074-7722, USA

Tel: +1-702-508-5200 Ext: 8047, Fax: +1-650-618-1417, Ph: +1-650-268-9744, Toll free: +1-800-216-6499

Email: americanvaccaines@conferenceseries.net, americanvaccines@vaccineconference.com

http://vaccines.global-summit.com/america/

18th Global Summit and Expo on

Vaccines & Vaccination

September 18-19, 2017 Houston, USA

18th Global Summit & Expo on

conferenceseries.com

Vaccines & Vaccination

September 18-19, 2017 Houston, USA

Program at A Glance

Day 1

Morning Sessions

Reception/Registration	08.00-09.00	
	Time	General Session
Least of 3 Keynote/Plenary Talks	09.00-09.15	Inaugural Address
	09.15-09.45	Keynote/Plenary Talk 1
	09.45-10.15	Keynote/Plenary Talk 2
	10.15-10.45	Keynote/Plenary Talk 3
Panel Discussions/Group Photo		
Coffee/Tea Break 10.45-11.00 (Networking)		
11.00-12.40	Vaccines & Immunization | Human vaccines-Infectious & Non-infectious | Modern Technologies in Vaccine Discovery & Development	
Lunch Break 12.40-13.30		
13.30-15.30	Vaccine Adjuvants & Delivery Technologies | Translational, Clinical Evaluation & Field Trials of Vaccines	
Coffee/Tea Break 15.30-15.45 (Networking)		
15.45-17.25	Workshop	

Day 2

Morning Sessions

	Time	Session 1	Session 2
09.00-10.40		Keynote Forum	Cancer Vaccines & Immunotherapy |Child vaccination & Immunization |Recombinant Vaccines
Coffee/Tea Break 10.40-10.55 (Networking)			
10.55-12.35		5 Speakers (20 Mins Each)	Travel Immunization | Vaccine safety & Efficacy | Vaccines Preclinical & Clinical Trials
Lunch Break 12.35-13.25			

Evening Sessions

13.25-15.05	5 Speakers (20 Mins Each)	Veterinary Vaccines | Influenza and Respiratory Vaccine
Coffee/Tea Break 15.05-15.20 (Networking)		
15.20-17.00	5 Speakers (20 Mins Each)	HIV/AIDS Vaccines | HPV & Hepatitis Vaccines

NOTE: Program Schedule is subject to change with final allotment of the speaker slots

For more Details PS: http://vaccines.global-summit.com/america/

americanvaccines@conferenceseries.net | americanvaccines@vaccineconference.com

Glimpses of Vaccines Conferences




















Major Scientific Sessions

- Vaccines & Immunization
- Human vaccines-Infectious & Non-infectious
- Modern Technologies in Vaccine Discovery & Development
- Vaccine Adjuvants & Delivery Technologies
- Translational, Clinical Evaluation & Field Trials of Vaccines
- Cancer Vaccines & Immunotherapy
- Child vaccination & Immunization
- Recombinant Vaccines
- Travel Immunization
- Vaccine safety & Efficacy
- Vaccines Preclinical & Clinical Trials
- Veterinary Vaccines
- Influenza and Respiratory Vaccine
- HIV/AIDS Vaccines
- HPV & Hepatitis Vaccines

Best Poster Award



- You will be given about 5-7 minutes to present your poster including questions and answers. Judges may pose questions during the evaluation of the poster
- Judges will even evaluate the student's enthusiasm towards their study, interest and knowledge in the area of their research
- The winners will be announced at the closing ceremony of the conference. The decision of the winner will be withdrawn if the winner/winners is/are not present at the time of announcement
- Apart from the judging time you may also be present at the poster to share your research with interested delegates



Young Researchers Forum

- Present your research through oral presentations
- Learn about career development and the latest research tools and technologies in your field
- This forum will give pertinent and timely information to those who conduct research and those who use and benefit from research
- Develop a foundation for collaboration among young researchers
- The forum will provide an opportunity for collegial interaction with other young investigators and established senior investigators across the globe
- Interact and share ideas with both peers and mentors

General Queries
vaccines@conferenceseries.com

Conference Venue


Houston, USA

Contact us
America: Conference Series LLC
Vaccines 2017
2360 Corporate Circle., Suite 400 Henderson,
NV 89074-7722, USA
Phone: +1-888-843-8169, Fax: +1-650-618-1417,
Toll free: +1-800-216-6499
Email: **americanvaccines@conferenceseries.net**
americanvaccines@vaccineconference.com


Contact us
UK: Conference Series LLC
Vaccines 2017
Heathrow Stockley Park Lakeside House
1 Furzeground Way, Heathrow
UB11 1BD, UK
Tel: +1-800-216-6499
Email: **americanvaccines@conferenceseries.net**
americanvaccines@vaccineconference.com

Contact us
Asia-Pacific: Conference Series LLC
Vaccines 2017
Divyasree Building, Raidurg
6th Floor, North Block
Hyderabad 500032, INDIA
Tel: 040-33432334
Email: **americanvaccines@conferenceseries.net**
americanvaccines@vaccineconference.com

Best Tourist Destinations in Houston



Houston Museum of Natural Science



Houston Space Centre



Houston Museum of Fine Arts



Water Wall



Houston Zoo



Glenwod Cementary Houston



Art Car Museum Houston



Houston Downtown Aquarium



Revention Music Centre

About Houston

Houston is the populous city in Texas and the fourth most populous city in the United States. According to the 2012 U.S. Census estimates, the city had a population of 2.16 million people within a land area of 599.6 square miles. Houston is the seat of Harris County, and its metropolitan area is the fifth-most populated in the U.S. The city was named after former General Sam Houston, who was president of the Republic of Texas and had commanded and won at the Battle of San Jacinto 25 miles east of where the city was established. The burgeoning port and railroad industry, combined with oil discovery in 1901, has induced continual surges in the city's population. In the mid-twentieth century, Houston became the home of the Texas Medical Center—the world's largest concentration of healthcare and research institutions—and NASA's Johnson Space Center, where the Mission Control Center is located. Houston is multicultural, in part because of its many academic institutions and strong industries as well as being a major port city. Houston is recognized worldwide for its energy industry particularly for oil and natural gas as well as for biomedical research and aeronautics. Renewable energy sources wind and solar are also growing economic bases in Houston. The ship channel is also a large part of Houston's economic base.

Alive with energy and rich in diversity, Houston is a dynamic mix of imagination, talent and first-class attractions that makes it a world-class city. Home to a vibrant economy, beautiful surroundings and a population full of optimism and spirit, it's no wonder that Houston is a popular international destination. Of the 10 most populous U.S. cities, Houston has the most total area of parks and green space, The city also has over 200 additional green space totaling over 19,600 acres that are managed by the city including the Houston Arboretum and Nature Centre.



Scientific Program

Day 1 **November 30, 2015**

Registrations

Tiburon

OMICS International
conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Title: Active vaccination strategies to prevent and reverse Alzheimer's Disease (AD)
Michael G Agadjanyan, University of California, USA
Title: Immunomodulatory properties of vitamins and flavonoids as vaccine adjuvants against infectious diseases
Michael Vajdy, EpitoGenesis, Inc., USA
Title: Dendritic vaccine delivery systems
Istvan Toth, University of Queensland, Australia

Coffee Break: @ Foyer

Special Session on

Anti-cancer vaccines & hot breakthoughs
Marek Malecki, Phoenix Biomolecular Engineering Foundation, USA
Anti-tumor activity of a pharmaceutical grade, plant-derived TLR-4-agonist in the 4T1 post-resection metastatic breast cancer model
Michael G Agadjanyan, University of California, USA

Track 1: Ebola Vaccines
Track 2: Veterinary Vaccines
Track 3: Vaccination in Pregnancy, Newborns and the Elderly Populations
Track 5: Innate and Adaptive Immune Responses to Vaccination
Track 7: Vaccinations Focusing on Induction of B or T cell Responses
Track 18: Flu Vaccines, Influenza and more

Session Chair: Haval Shirwan, University of Louisville, USA
Session Co-Chair: Michael Vajdy, Epito Genesis, Inc., USA

Session Introduction

Title: Single-cycle replicating adenovirus vectors
Michael A Barry, Mayo Clinic, USA
Title: Cost-effectiveness of microneedle patches in childhood measles vaccination program
Bishwa B Adhikari, CDC/OID/NCEZID, USA

Group Photo

Lunch Break: @ Redwood

Title: Cationic lipids efficiently deliver self-amplifying Rep RNA for translation in DC and monocytes
Pavlos C Englezou, The Institute of Virology and Immunology (IVI), Germany
Title: Investigator prospective on vaccine studies protocol development and execution
William B Smith, FACC, (VRG and NOCCR), USA
Title: Booster immunization with aerosolized MMR vaccine, and its potential use in elimination strategies for measles and Rubella
Jose-Luis Diaz-Ortega, Instituto Nacional de Salud Pública (INSP), Mexico

Title: Development of the *Ebolavirus* vaccine using a genetically modified dual serotype recombinant vesicular stomatitis virus platform technology
C Yong Kang, University of Western Ontario, Canada

Title: Protection from H5N1 influenza virus challenge with a single dose HA subunit protein vaccine
Alison McCormick, Touro University, USA

Coffee Break: @ Foyer

Title: Assessment of hepatitis B vaccination coverage in a population of workers
Frederic J Deschamps, University Hospital of Reims, France
Title: Development of Malaria vaccines using an alpahvirus virus-like particle (VLP) platform
Wataru Akahata, VLP Therapeutics, USA
Title: Chicken bone marrow-derived dendritic cells induced by a Salmonella vaccine candidate
John Hwa Lee, Chonbuk National University, Korea
Title: Human, synthetic, immuno-genomically-designed antibodies (sigAbs)™ to assess patients diagnosed with HER2+ breast cancer for therapeutic vaccines
Marek Malecki, Phoenix Biomolecular Engineering Foundation, USA

Panel Discussion

Day 2 December 01, 2015

Tiburon

Keynote Forum

Title: Exploiting synergy between TNFR and TLR4 signaling for the development of adjuvant systems
Haval Shirwan, University of Louisville, USA
Title: A need for T-cell based vaccines against AIDS lentiviruses
Janet K Yamamoto, University of Florida, USA

Coffee Break: @ Foyer

Workshop on

Investigator prospective on vaccine studies protocol development and execution
William B Smith, FACC, (VRG and NOCCR), USA

Workshop on

Reconsidering the importance of T-cell immunity in an effective HIV vaccine
Janet K Yamamoto, University of Florida, USA

Lunch Break: @ Redwood

Track 9: Vaccines Against Infectious Diseases and Cancers
Track 14: Age-specific Immune Response to Vaccination
Track 15: Vaccines for Survival Diseases
Track 16: Cancer Vaccines
Track 17: HIV/AIDS, STD & STI

Session Chair: Michael Vajdy, Epito Genesis, Inc., USA
Session Co-Chair: Haval Shirwan, University of Louisville, USA

Session Introduction

Title: Affinity, and beyond: Comparison of a Biacore affinity assay with a cell-based potency assay for an anti-bacterial Fab' fragment
Jason Szeto, Sanofi Pasteur, Canada
Title: Innate immunity in cardiology: Vessel and valve
Ming-Yow Hung, Taipei Medical University, Taiwan
Title: Strategies for neglected infection diseases, the example of diphtheria
Frederic J Deschamps, University Hospital of Reims, France
Title: Optimizing the immunization strategy to prevent hepatitis E virus (HEV) zoonotic transmission by vaccinating animals
Ling Wang, Peking University Health Science Center, China

Title: Novel mechanisms of adjuvanticity implied from *in vitro* studies with bacterial toxins
Toufic O Nashar, Tuskegee University, USA

Coffee Break: @ Foyer

Title: Towards mucosal DNA delivery: structural modularity in vaccine platform design
R Holland Cheng, University of California, USA
Title: Factors influencing low immunization coverage among children between 12 - 23 months in East Pokot, Baringo County Kenya
Elizabeth kiptoo, Mount Kenya University, Kenya

Posters Session: @ Foyer	
P1	**Title: Immuno-targeting ENO1 as a novel strategy for cancer therapy**
	NENG-YAO SHIH, National Institute of Cancer Research, Taiwan
P2	**Title: An H5N1 based matrix protein 2 ectodomain tetrameric peptide vaccine provided cross-protection against lethal infection of H7N9 *Influenza virus***
	Bo-Jian Zheng, University of Hong Kong, Hong Kong
P3	**Title: *Bacillus subtilis* spore as edible vaccine carrier's**
	Michał Obuchowski, Medical University of Gdańsk, Poland
P4	**Title: Immune response to UreA and UreB of *Helicobacter acinonychis* and delivered on the surface of recombinant *Bacillus subtilis* spores**
	Krzysztof Hinc, Medical University of Gdańsk, Poland
P5	**Title: The impact of the classical, lectin and alternative pathways of complement activation on protective immunity against *Streptococcus Pneumoniae* infection following vaccination with *Pneumococcal Polysaccharide* Vaccine**
	Youssef ALAOFI, University of Leicester, UK
P6	**Title: Immunization with Salmonella PrgI and SipD Type III Secretion Proteins protects mice against intestinal infection by *Salmonella typhimurium***
	Bakhos Jneid, CEA de Saclay, France
P7	**Title: Novel mechanisms of adjuvanticity implied from *in vitro* studies with bacterial toxins**
	Rawah Faraj, Tuskegee University, Tuskegee
P8	**Title: Encapsulin, an effective antigen-delivery nanocarrier, leads to antigen specific cytotoxic T cell activation and tumor rejection**
	Bongseo Choi, Ulsan National Institute of Science and Technology, Korea
P9	**Title: Generation of an attenuated Salmonella expressing adhesins and toxins of *Pasteurella multocida* and *Bordetella bronchiseptica* for pig progressive atrophic rhinitis, and evaluation of its immune responses**
	John Hwa Lee, Chonbuk National University, Korea
Panel Discussion	

Day 3 December 02, 2015

Tiburon

Track 8: Novel Approaches in Design of Cellular and Molecular-Based Vaccines
Track 10: Manufacturing, Production, and Development of Vaccines
Track 11: Regulatory and Ethical Issues of Vaccines and Public Acceptance
Track 12: Translational, Clinical Evaluation and Field Trials of Vaccines
Track 19: Molecular Virology and Immunology

Session Chair: Michael Vajdy, Epito Genesis, Inc., USA
Session Co-chair: Haval Shirwan, University of Louisville, USA

Session Introduction

Title: Novel strategy for safe and effective vaccine delivery to elicit cell-mediated immunity against infectious and malignant diseases
Kwang Poo Chang, Chicago Medical School/RFUMS, USA

Title: Worldwide success in eliminating mother to child transmission of HBV: A paradigm for passive-active immunization against HIV
Ramani A Aiyer, TheraBiol, Inc. USA
Title: Characterization of the putative polysaccharide gene cluster in multidrug-resistant *E. faecium* to develop a targeted therapy (vaccine)
Liaqat Ali, University Medical Center Freiburg, Germany

Coffee Break: @ Foyer

Title: Biobran/MGN-3, Arabinoxylan rice bran, for the treatment of chronic hepatitis C
Eman Medhat Hassan, Cairo University School of Medicine, Egypt
Title: A retrospective analysis of the burden of HIV-related admissions & mortality in Princess Marina Hospital, Gaborone in the year 2000
Mooketsi Molefi, University of Botswana, Botswana
Title: TCF4 may act as a tumor suppressor gene in colorectal carcinogenesis
Rabia Farooq, Govt. Medical College, India

Video Presentation

Title: Vaccine cold chain & logistics: A pharmacist's perspective
Tarek Kilani, Emirates French Hospital, UAE

Lunch Break: @ Redwood

e-POSTERS

EP1	**Title: Proteoliposomes obtained from nonpathogenic mycobacteria as a protective vaccine candidates against tuberculosis infection**
	Nadine Alvarez Cabrera, Finlay Institute, Cuba
EP2	**Title: Dual infection by influenza viruses and human rhinoviruses in patients with acute respiratory infection in Ahvaz by 2012-2013**
	Amir Pouremamali, Ahvaz Jundi Shapur University of Medical Sciences, Iran
EP3	**Title: Surveillance and epidemiology of hepatitis B, C, D and G in Khuzestan Province, Southwest Iran - A review**
	Amir Pouremamali, Ahvaz Jundi Shapur University of Medical Sciences, Iran
EP4	**Title: The importance of using herbs in the prophylaxis of infectious disease in immunosuppressed patients**
	Roman Luminita, University of Bucharest, Romania
EP5	**Title: Vaccine developments against multi-resistant drug organisms: The role of bacteriophages**
	Elufisan Temidayo Oluyomi, Instituto Politecnico Nacional Mexico

Closing Ceremony



Bookmark your dates

11th Global Summit and Expo on

Vaccines & Vaccination

September 12-14, 2016 Pheonix, USA

Website: http://vaccines.global-summit.com/america/

OMICS Group Inc.
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
contact@omicsgroup.com

OMICS International
5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USA
Ph: +1-650-268-9744
Fax: +1-650-618-1414
contact.americas@omicsonline.org

OMICS International
SEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC City
Hyderabad-500081, Telangana, INDIA
Ph: 040-40131823, 040-47482222
contact.asiapacific@omicsonline.org

Toll free
USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048

Scientific Program

OMICS Group Conferences
Accelerating Scientific Discovery

4th International Conference on
Vaccines & Vaccination

September 24-26, 2014 Valencia Convention Centre, Spain

Sponsors & Exhibitors

SANOFI PASTEUR | VACCINOGEN Turning Cancer On Itself™ | GenPhar | C.T.L. Cellular Technology Ltd.



Media Partners

absave | labsave | biosave | BioSpectrum | Conference locate.com | contract-biotechnology.com | Globalsave media group | HPV Today
iptechex | BioPharm Insight The Story Behind the Data | MNT Medical News Today | Medical News TODAY | Pharma Mirror | PharmaVision | Technology Networks.com Scientific Communities | Gov Events

"Organize your Events at OMICS Group Conferences"

Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to *symposia@omicsonline.org*

OMICS Group Conferences
5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA
Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499
Email: *vaccines2014@omicsonline.net*

Day 1 September 24, 2014

Registrations

Auditorium 3A

OMICS Group Conferences
Accelerating Scientific Discovery

Opening Ceremony

Keynote Forum

Introduction

Ray Spier
University of Surrey, UK

Michael G Hanna
Vaccinogen, Inc., USA

Nikolai Petrovsky
Flinders Medical Centre Research, Australia

Group Photo

Coffee Break @ Auditorium 3 Foyer

Vaccine adjuvants

Session Chair: Nikolai Petrovsky, Flinders Medical Centre Research, Australia

Title: Inter-bilayer cross-linked multi-lamellar vesicles (ICMVs) for efficient co-delivery of antigen and adjuvant payloads
Alan R Shaw, Vedantra Pharmaceuticals, USA

Title: Adjuvant-guidance of T cell responses
Magdalena Tary-Lehmann, Cellular Technology Limited, USA

Title: Antibody targeting of human T cell CD27 identifies genes and pathways related to inflammation
Venky Ramakrishna, Celldex Therapeutics, USA

Title: Evaluation of ZOSTAVAX® via the intradermal route using the MicronJet™
Brian K. Meyer, Merck & Co., USA

Title: Universal influenza vaccines: Prevention of infection against matched and mismatched strains
Harry Kleanthous, Sanofi-Pasteur, Inc., USA

Title: DNA vaccines which encode natural adjuvants are more effective than canonical DNA vaccines
Eric James Gowans, The University of Adelaide, South Australia

Lunch Break @ Multi Purpose Hall 2

Title: Immune memory resilience, a new way of evaluating adjuvants
Jean-Pierre Y Scheerlinck, The University of Melbourne, Australia

Title: Novel lipid based adjuvants and delivery systems for induction of CD8 T cell immunity
Lakshmi Krishnan, National Research Council-Human Health Therapeutics, Canada

Title: Establishment of lipid-based immunogens for the development of novel subunit vaccines
Chih-Hsiang Leng, National Health Research Institutes, Taiwan

Title: Highly immunogenic C-terminal binding domain of *Clostridium difficile* toxin a stimulates dendritic cell maturation
Pele Choi-Sing Chong, National Health Research Institutes, Taiwan

Coffee Break @ Auditorium 3 Foyer

Title: The Cronobacter sakazakii ESP2949-1 phage induces dendritic cell maturation via activation of nuclear factor-κB and IL-12p40 in murine bone marrow
Hyo-Ihl Chang, Korea University, Korea

Title: Nasal administration of antigens using maltodextrin nanoparticles: A mechanistic study
Didier Betbeder, University of Luille2, France

Title: Stabilized liposomes carrying bee venom new formulation is the breakthrough of pain and anaphylaxis and death in mice under venom immunotherapy
Maria Helena Bueno da Costa, Scientific Consultant, France

Title: Live vaccine for equine influenza on the base of cold-adapted recombinant strain A/HKOtar/6:2/2010
Sandybayev Nurlan, Research Institute for Biological Safety Problems, Republic of Kazakhstan

Title: Polio outbreak in the Middle East: Update
Randa Hamadeh, Ministry of Public Health, Lebanon

Title: Outer membrane vesicle of bacteria: Friend or Foe?
Seyed Davar Siadat, Pasteur Institute of Iran, Iran

Title: Adjuvant properties of outer-membrane-vesicle in hepatitis B surface based vaccine
Arfa Moshiri, Shahid Beheshti University of Medical Sciences, Iran

Title: Role of interferon gamma as immune adjuvant in *Labeor ohita*
Megha Kadam Bedekar, Central Institute of Fisheries Education, India

Panel Discussion

Biodefense vaccine

Session Chair: Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA

Title: Finding a safe, efficacious and stable vaccine in the ricin protein fold
Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA

Title: A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation
Connie S Schmaljohn, United States Army Medical Research Institute of Infectious Diseases, USA

Title: MVA-BN® (IMVANEX®/IMVAMUNE®): A non-replicating, new generation smallpox vaccine available for updating smallpox preparedness plans
Nathaly Arndtz-Wiedemann, Bavarian Nordic GmbH, Germany

Title: A vaccine pipeline: Using phage display for identification of immunogenic proteins and generation of human antibodies for diagnostics and therapy
Michael Hust, Technische Universität Braunschweig, Germany

Panel Discussion

Lunch Break @ Multi Purpose Hall 2

Veterinary vaccines

Session Chair: Jean L Patterson, Texas Biomedical Research Institute, USA

Title: Quality and consistency of cell culture media with a highlight on FMDV
Serge Ohreser, Merck Millipore, France

Title: Vaccine development at animal biosafety level four: Standards and challenges
Jean L Patterson, Texas Biomedical Research Institute, USA

Title: Low dose antigen exposure in extreme early life promotes adaptive immune response in lambs and piglets
Heather L Wilson, University of Saskatchewan, Canada

Title: Study immune correlates of vaccine-induced protective immunity against rotavirus infection and diarrhea using B cell deficient neonatal gnotobiotic pigs
Lijuan Yuan, Virginia Polytechnic Institute and State University, USA

Title: Targeting aminopeptidase N on enterocytes rapidly induces an IgA response in a pig model
Eric Cox, Ghent University, Belgium

Title: Use of ORF-1 product Rep in prevention and diagnosis of porcine circovirosis
Silvia Pellicer, World Pathol, Spain

Coffee Break @ Auditorium 3 Foyer

Title: Properties of ghost bacterial cells obtained by hybrid material with silver nanoparticles (PVA/ AgNps) as well as their opportunities for use in vaccine prophylactics
Daniela Pencheva, Bul Bio - NCIPD Ltd., Bulgaria

Title: Imapct of three inactivated bovine viral diarrhoea (BVD) vaccines on bulk milk p80 (NS3) ELISA readings in commercial irish dairy herds
Riona Sayers, Animal & Grassland Research and Innovation Center, Ireland

Title: Construction of Phix174 gene E mediated lysis system for generation of *Salmonella Enteritidis* ghost, and its evaluation as a vaccine candidate for the immunogenicity and protective efficacy against avian salmonellosis
Chetan V Jawale, Chonbuk National University, Republic of Korea

Title: Use of viral interference against avian influenza and establishment of protection levels in field outbreaks in Mexico
Inkar Castellanos, Viren SA de CV, Mexico

Panel Discussion

Day 2 September 25, 2014

Auditorium 3A

Keynote Forum

Introduction

Geert Vanden Bossche
UNIVAC LLC., Belgium

Jeffrey Ulmer
Novartis Vaccines & Diagnostics, USA

Group Photo

Therapeutic vaccines for chronic infecti

Session Chair: Jeffrey Ulmer, Novartis Vaccines & Diagnostics, USA

Title: Mimogen-a new strategy for post-exposure vaccine development
Yuzhang Wu, Third Military Medical University, China

Title: Generation of robust immunity following DNA vaccine immunization enhanced by intradermal electroporation
Kate E Broderick, Inovio Pharmaceuticals, USA

Title: M2SR, a robust flu vaccine with long-lasting, cross-protective immunity
Pamuk Bilsel, Flugen Inc., USA

Coffee Break @ Auditorium 3 Foyer

Title: In vivo electroporation for improvement of therapeutic DNA vaccine against chronic hepatitis B infection
Lucyna Cova, INSERM, France

Title: A Synthetic multi-antigen approach targeting *Plasmodium falciparum* malaria
Bernadette Ferraro, University of Pennsylvania, USA
Title: Pneumococcal infections and vaccination
Birgitta Henriques-Normark, Karolinska Institute, Sweden
Title: Heat shock protein complex vaccines against mucosal pathogenic bacteria
Phil Sutton, Murdoch Childrens Research Institute, Australia
Title: Upgrading the 100 year-old BCG vaccine
Zakaria Hmama, University of British Columbia, Canada

Lunch Break @ Multi Purpose Hall 2

Title: Immunization with neuraminidase deficient influenza virus is highly immunogenic and non-pathogenic to wild type and immunocompromised mice
Alexandre M. Vieira Machado - Fiocruz, Rene Rachou Research Center, Brazil
Title: Design and evaluation of a novel OspA-based vaccine for the prevention of Lyme borreliosis
Andreas Meinke, Valneva Austria GmbH, Austria
Title: Therapeutic vaccines for drug-resistant tuberculosis
Tjip van der Werf, University of Groningen, The Netherlands
Title: Vaccination in risk groups with special focus on non-responsiveness to routine vaccines
Ursula Wiedermann, Medical University of Vienna, Austria
Title: Post challenging effects of new formulation of leishmania major antigen in Balb/c mice
Latifynia Afshineh, Tehran University of Medical Sciences, Iran

Coffee Break @ Auditorium 3 Foyer

Title: Immunological studies on tetanus toxoid
Rakesh Kumar, Serum Institute of India Limited, India
Title: Process development and immunogenicity studies on a serogroup 'X' meningococcal polysaccharide conjugate vaccine
Srinivas Reddy, Serum Institute of India Ltd., India
Title: Self-adjuvanting promiscuous peptide of Mycobacterium tuberculosis augments polyfunctional Th17 cells and evokes better memory T cell response than BCG
Javed N Agrewala, CSIR - Institute of Microbial Technology, India
Title: Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with *Mycobacterium tuberculosis*
Xueqiong Wu, the 309th Hospital of Chinese PLA, China
Title: Speciation of chromium in medicinal plants from selected farms in the vicinity of ferrochrome
Isiaka Alade Owolabi, Tshwane University of Technology, South Africa

Panel Discussion

Special Session for Students: Nikolai Petrovsky @ Community Hall 1-2
Scientific writing, Journal review, Grant writing, Strategies for building a scientific career and Scientific careers outside of research

Breakout @ Committee Room 6-7

Cancer vaccines

Session Chair: Michael G Hanna, Vaccinogen, Inc., USA
Title: From viruses to tumor associated antigen cancer vaccines
Giulio Tarro, Temple University Center for Biotechnology, USA
Title: Measles Virus vaccine infects tumor cells and induces dendritic cells (DC) maturation and tumor antigen cross-presentation
Marc GREGOIRE, Institut de Recherche en Sante Universite de Nantes, INSERM, France
Title: Personalized therapeutic cancer vaccine development to treat metastatic diseases
Periasamy Selvaraj, Emory University, USA

Coffee Break @ Auditorium 3 Foyer

Title: Teaching self-destructing *Salmonella* new tricks to fight cancer
Wei Kong, Arizona State University, USA
Title: DC targeting skin vaccines for improved cancer immunotherapy
Yvette van Kooyk, VU Unversity Medical Center, The Netherlands
Title: Acceptability of human papillomavirus vaccine: A survey among master of business administration students in KwaZulu-Natal, South Africa
M E Hoque, University of KwaZulu-Natal, South Africa

Panel Discussion

AIDS/HIV vaccine

Title: Antigenicity, structure and immunogenicity of the HIV-1 trimeric envelope glycoprotein spike
Richard T Wyatt, The Scripps Research Institute La Jolla, USA

Lunch Break @ Multi Purpose Hall 2

Title: Application of neutralization fingerprints in delineating antibody recognition in HIV-1 sera and antibody epitope prediction
Gwo-Yu Chuang, National Institutes of Health, USA
Title: The balance of cellular and humoral immunity determines the level of protection offered by an HIV vaccine in macaque models of HIV infection
Timothy Fouts, Profectus BioSciences, Inc., USA
Title: VAC-3S vaccine, a novel approach to the therapeutic management of HIV Infection. Overview of phase I and phase II clinical vaccine development programs
Raphael Ho Tsong Fang, InnaVirVax, France
Title: Characterization of a potent and broad neutralizing antibody that specifically recognizes a point-substitution in the 3S motif of the HIV-1 gp41 protein
Patrice DEBRE, INSERM, France

Title: Glycosylation of envelope gp120 is affected by producer cell type and impacts HIV-1 recognition by virus-specific antibodies and cell infection
Milan Raska, Palacky University, Czech Republic

Coffee Break @ Auditorium 3 Foyer

Title: DNA vaccination against drug resistance in chronic viral infections, example of HIV-1
Maria ISAGULIANTS, Karolinska Institutet, Sweden; Riga Stradins Univeristy, Latvia
Title: Evaluation of immune response in small animal models by in vivo imaging
Stefan Petkov, Karolinska Institutet, Sweden
Title: Human clinical trial of SAV001 prophylactic HIV vaccine and a new strategy for the development of therapeutic HIV vaccine
Chil-Yong Kang, The University of Western Ontario, Canadav

Panel Discussion

Vaccine antigen modeling

Title: Optimizing the delivery of novel immune potentiators within vaccine drug products
Manmohan Singh, Novartis Vaccines, USA
Title: Natural killer cell subsets display helper and suppressor effects in modulating host viral responses *in vivo*
William J Murphy, UC Davis School of Medicine, USA
Title: Strategies of antigen retargeting for improvement of DNA vaccine performance
Elizaveta Starodubova, Karolinska Institutet, Sweden
Title: Cellular vaccines in Listeriosis: Role of the *listeria* antigen GAPDH
Carmen Alvarez-Dominguez, Instituto de Formacion e Investigacion Marques de Valdecilla, Spain
Title: Regulation of STING expression via the RIG-I dependent RNA sensing pathway
Rongtuan Lin, McGill University, Canada
Title: Cell engineering and antibiotic-free selection for vaccinal antigens production in *E. coli*: The ultimate sophistication to combine safety and productivity
Regis Sodoyer, Sanofi Pasteur, France
Title: Leishmania recombinant antigen modulates the macrophage effector functions synergizing anti-leishmanial effects of miltefosine to facilitate early clearance of intracellular parasites
Sunil K Arora, PGIMER, India

Day 3 September 26, 2014

Auditorium 3A

Immuno-informatics in vaccine design

Session Chair: Malcolm E Thomas, Arbovax., Inc., USA

Title: Immunization and human rights
Obradovic Zarema, University of Sarajevo, Bosnia and Herzegovina
Title: SIgN's clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials
Brian Abel, Singapore Immunology Network, Singapore
Title: Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children
Katie Ewer, University of Oxford, UK
Title: The common computer-based influenza vaccination/epidemics surrveilance system: Challenges and opportunities for primary health care in EU countries
Ljiljana Majnaric Trtrica, JJ Strossmayer University, Croatia
Title: The development of tuberculosis subunit vaccine EAMMH and regulation of vaccine induced immune memory by Rapamycin
Bingdong Zhu, Lanzhou University, China
Title: Immunization programme in Indonesia: Overview- (Focusing on *Streptococcus Pneumonia* whole-cell vaccine)
Julitasari Sundoro, Indonesian Technical Advisory Group on Immunization, Indonesia

Panel Discussion

Coffee Break @ Auditorium 3 Foyer

Vaccine formulation issues

Title: Unique nanofabrication of antigens and adjuvants that effectively induces protective antibody and T cell responses
Frank J Malinoski, Liquidia Technologies Inc., USA
Title: Development of a carbohydrate-based vaccine against meningococcal serogroup X infection
Francesco Berti, Novartis Vaccines, Italy
Title: Effect of the inclusion of "contemporary" *B. pertussis* strains in the vaccine composition on temporal trends in *B. pertussis* population
Tatjana Pljesa, Institute of Virology, Vaccines and Sera Torlak, Serbia
Title: Specificities of health economics in the area of vaccines evaluation
Maarten J Postma, University of Groningen, The Netherlands
Title: The effect of new leishmania vaccine against Th1, Th2 as well as increasing of spleen white pulp size in Bulb/c mice after repeated exposure
Latifynia Afshineh, Tehran University of Medical Sciences, Iran

Panel Discussion

Lunch Break @ Multi Purpose Hall 2

Unconventional vaccines

Title: A novel approach to the development of arboviral vaccines for dengue and chikungunya virus
Malcolm E Thomas, Arbovax., Inc., USA
Title: Strategies toward developing a universal ExPEC vaccine capable of broad protection
Melha Mellata, Arizona State University, USA

Title: The vaxonella platform for oral recombinant vaccine delivery
Rocky M Cranenburgh, Prokarium Ltd., UK
Title: Oral vaccine platform elicits neutralizing antibody responses to influenza
Sean Tucker, Vaxart, Inc., USA
Title: A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of influenza B globular head vaccines
Langzhou Song, VaxInnate Corporation, USA

Coffee Break @ Auditorium 3 Foyer

Title: Responsibility: A "first person ethics" for vaccination
Fermin J Gonzalez-Melado, Pontifical Institute "John Paul II" for Studies on Marriage and Family, Spain
Title: Development of a truly improved whooping cough vaccine
Marcel Thalen, Iliad Biotechnologies, Scotland
Title: Translational development and preclinical efficacy of a multiantigen T cell epitope-enriched DNA vaccine against *Leishmaniasis*
Christiane Juhls, MOLOGEN AG, Germany
Title: Oral infections in Guinea Conakry
Sylvain Haba, Centre Des Soins Medico-Tradi-Spirituels Talithakoumi, Guinea Conakry

Panel Discussion

Poster Presentations @ Auditorium 3 Foyer
Day-2

VAC-001 **Title: Using NYVAC vectors as vaccine candidates for Leishmaniasis**
Ernesto Mejias Perez, Centro Nacional de Biotecnologia, Spain

VAC-002 **Title: Enhancement of antigen-specific CD4 T cell response through spacer modification in vaccinia virus promoters**
Mauro Di Pilato, Centro Nacional de Biotecnologia, Spain

VAC-003 **Title: IL-34 suppresses Candida albicans induced TNF-a production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression**
Rong Xu, Cardiff University, UK

VAC-004 **Title: Protection of chickens against *Chlamydia psittaci* challenge by mucosal immunization with the major outer membrane protein**
Daisy Vanrompay, Ghent University, Belgium

VAC-005 **Title: The single intradermal cervical comparative testand Johne's disease ELISA diagnostics**
Aideen Kennedy, Animal & Grassland Research and Innovation Centre, Ireland

VAC-006 **Title: Antigen on nanoparticles enhances anti-tumor immune responses as well as humoral antibody responses *in vivo***
Junichiro Mizuguchi, Tokyo Medical University, Japan

VAC-007 **Title: Hepatitis B immunizationstatus of a miscellaneous population of workers**
Frederic DESCHAMPS, University Hospital of Reims, France

VAC-008 **Title: Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic boosting in mice**
Silvia Vendetti, Istituto Superiore di Sanita, Italy

VAC-009 **Title: Experimental chagas disease: Vaccination with *Trypanosoma rangeli* modulate the innate immune response in mice challenged with *Trypanosoma cruzi***
Beatriz Basso, National University of Cordoba, Argentina

VAC-010 **Title: Effect of preventive and therapeutic vaccination schedules with *Trypanosoma rangeli* against *Trypanosoma cruzi* infection in a mouse model of Chagas' disease**
Beatriz Basso, National University of Cordoba, Argentina

VAC-011 **Title: Generation of genetically inactivated *Salmonella Gallinarum* ghost and evaluation of its potential as an effective inactivated vaccine candidate against fowl typhoid**
Chetan V Jawale, Chonbuk National University, Korea

VAC-012 **Title: Construction of tightly regulated E-lysis cassette for production of genetically inactivated *Salmonella* Enteritidisghost**
Chetan V. Jawale, Chonbuk National University, Korea

VAC-013 **Title: Increasing of alive plague vaccine efficiency**
Ponomaryova Tatyana, Kazakh Scientific Center of Quarantine and Zoonotic Diseases, Kazakhstan

VAC-014 **Title: Double-blind randomized placebo-controlled trial to evaluate cell-mediated immunity and safety of the herpes zoster vaccine in elderly patients with diabetes**
Atsuko Hata, The Tazuke Kofukai Medical Research Institute, Japan

VAC-015 **Title: Analysis of phage displayed antibody fragment - pros and cons of Phage ELISA and RISE methods**
Barbara Kalenik, Institute of Biochemistry and Biophysics Polish Academy of Sciences, Poland

VAC-016 **Title: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa**
Athina KILPELAINEN, Karolinska Institutet, Sweden

VAC-017 **Title: Retargeting of HIV reverse transcriptase to MHC class II processing improves its immunogenicity**
Anastasia Latanova, Karolinska Institutet, Sweden

VAC-018 **Title: Lipopolysaccharide of *Coxiella burnetii*. A promising candidate molecule in a search for a new Q fever vaccine**
Rudolf Toman, Slovak Academy of Sciences, Slovak Republic

VAC-019 **Title: Long-term immune response to Hepatitis B Virus (HBV) vaccine among type 1 diabetic students: Do they need a booster?**
Engy M. El-Ghitany, Alexandria University, Egypt

VAC-020 **Title: Bivalent candidate vaccine against HCV and HIV-1: Construction and biological evaluation**
Mohammad Reza Aghasadeghi, Pasteur Institute of Iran, **Iran**

VAC-021 **Title: An early report on a local project about primary health care to improve the communication and the compliance in the elderly for vaccinal campaigns against inluenza**
Filippo de Nicolellis, Primary Health Care, Italy

VAC-022 **Title: Cyclic GMP-AMP has mucosal adjuvant activity in mice**
Christina Rueckert, Helmholtz Center for Infection Research, Germany

VAC-023 **Title: Local and systemic antibody and cell-mediated immune response after vaccination and infection with porcine respiratory and reproduction system (PRRS) virus**
Miroslav Toman, Veterinary Research Institute, Czech Republic

VAC-024 **Title: Using monoclonal antibodies to understand the molecular basis for the cross bactericidal activity of NHBA antigen**
Claudia Facciotti, Novartis, Italy

VAC-025 **Title: Expression profile of cytokine transcripts and Cell mediated immune response in peripheral blood mononuclear cells of sheep following vaccination of pentavalent bluetongue vaccine**
Molalegne Bitew, Jimma University, Ethiopia

VAC-026 **Title: In vitro molecular analysis of ribosomal initiation complexes assembly and RNA-protein interactions during the initiation of translation of a prototype Coxsackievirus B3 and a live-attenuated Sabin 3-like RNAs**
Amira SOUII, Universite de Tunis El Manar, Tunisia



Bookmark your dates

OMICS Group Conferences
Accelerating Scientific Discovery

Asia Pacific Global Summit and Expo on
Vaccines & Vaccination
June 01-03, 2015 Brisbane, Australia

OMICS Group Conferences
Accelerating Scientific Discovery

Euro Global Summit and Expo on
Vaccines & Vaccination
August 17-19, 2015 Birmingham, UK

OMICS Group Conferences
Accelerating Scientific Discovery

Indo Global Summit and Expo on
Vaccines & Vaccination
September 28-30, 2015 New Delhi, India

OMICS Group Conferences
Accelerating Scientific Discovery

Dubai Global Summit and Expo on
Vaccines & Vaccination
September 28-30, 2015 Dubai, UAE

OMICS Group Conferences
Accelerating Scientific Discovery

American Global Summit and Expo on
Vaccines & Vaccination
October 05-07, 2015 San Francisco, USA

OMICS Group Inc.
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
contact@omicsgroup.com

OMICS Publishing Group
5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USA
Ph: +1-650-268-9744
Fax: +1-650-618-1414
contact.americas@omicsonline.org

OMICS Group
SEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC City
Hyderabad-500081, Telangana, INDIA
Ph: 040-40131823, 040-47482222
contact.asiapacific@omicsonline.org

Toll free
USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048

111th OMICS Group Conference

Scientific Program

OMICS Group Conferences
Accelerating Scientific Discovery

3rd International Conference on Vaccines & Vaccination

July 29-31, 2013 Embassy Suites Las Vegas, NV, USA



Sponsor & Exhibitor

GenPhar

Desert King International

Media Partners

Bentham Science Publishers Ltd.

MEDtube

Scholars Central

"Organize your Events at OMICS Group Conferences"

Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to *symposia@omicsonline.org*

OMICS Group Conferences
5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA
Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499
Email: *vaccines2013@omicsonline.us*

Day 1 July 29, 2013

Registrations

Flamingo Ballroom

OMICS Group Conferences
Accelerating Scientific Discovery

Opening Ceremony

Moderator: Haval Shirwan
Executive Editor, Journal of Clinical & Cellular Immunology, OMICS Group Inc., USA
University of Louisville, USA

Workshop
Implementing a core team process to maximize efficiencies and minimize costs in the start-up and conduct of clinical trials

Chair Person Brenda S. Atchison, The Alliance for Multispecialty Research, LLC, USA
Cynthia Dukes, ICON Clinical Research, USA
Evette Riegel, Beardsworth Consulting Group, USA
Cody Towler, Clinical Research Consortium , USA

Group Photo & Coffee Break @ Atrium

Keynote Forum

Introduction

Peter L. Nara
Biological Mimetics, Inc., USA

Ara Hovanessian
CNRS Universite Paris Descartes, France

Malcolm Thomas
Arbovax Inc., USA

Lunch Break @ Atrium

Nikolai Petrovsky
Flinders University, Australia

John Dong
GenPhar Inc., USA

Track 1: Innate and Adaptive Immune Responses to Vaccination
Track 2: Vaccinations Focusing on Induction of B or T cell Responses

Session Chair: Nikolai Petrovsky, Flinders University, Australia
Session Co-Chair: Esma S. Yolcu, University of Louisville, USA

Session Introduction

Title: Stabilization and drying of vaccines for novel delivery
Robert E. Sievers, University of Colorado, USA
Title: Adenovirus vector-induced innate-adaptive protective immunity duo against viral and bacterial infections
De-chu C. Tang, International Vaccine Institute, Korea
Title: Electric fields and IL-18 synergistically stimulate dendritic cell activity
Xiaoqing Wei, Cardiff University, UK
Title: Negative vaccination with donor splenocytes engineered with FasL as an effective mean of inducing transplantation tolerance
Esma S. Yolcu, University of Louisville, USA

Coffee Break @ Atrium

Title: Design and clinical evaluation of a novel self-adjuvanting peptide-based pan influenza A T-cell vaccine
Campbell Bunce, Immune Targeting Systems Ltd, UK
Title: Strategies for generation of broadly cross-neutralising anti-influenza vaccine responses
Nikolai Petrovsky, Flinders University, Australia
Title: New strategies to present an anti-candidiasis synthetic glycopeptide vaccine acceptable for human use
Hong Xin, LSUHSC & Children's Hospital Research Institute, USA
Title: Are there time period-related differences in the prophylactic effects of Bacille Calmette-Guerin intravesical instillation therapy? : Comparison of Japan and Western countries
Takehiko Okamura, J.A.Aichi Anjo Kosei Hospital, Japan

Title: Vaccine hyporesponse in healthy elderly subjects is associated with a decrease in B cell IFN responses: Data from functional proteomic analysis using single cell network profiling
Diane Longo, Nodality, USA

Panel Discussion

Cocktails: Sponsored by **Journal of Vaccines & Vaccination @ Atrium**

Day 2

Flamingo Ballroom

Track 3: Novel Approaches in Design of Cellular and Molecular-Based Vaccines

Session Chair: Nikolai Petrovsky, Flinders University, Australia
Session Co-Chair: Rajesh Kumar Sharma, University of Louisville, USA

Session Introduction

Title: Applications of the Vaccine Ontology (VO) in vaccine data integration and computer-assisted automated reasoning
Yongqun "Oliver" He, University of Michigan Medical School, USA
Title: Rational design of Synthetic Vaccine Particles (SVP) for therapeutic treatment of chronic diseases
Takashi Kei Kishimoto, Selecta Biociences, USA
Title: Efficacy of a mixture of synthetic peptides overlapping the conserved CBD1 epitope in gp41 of HIV-1 to protect against SHIV162P3 rectal challenge in cynomolgus macaques
Ara Hovanessian, CNRS - Université Paris Descartes, France
Title: Protection against influenza from RNActiveÂ® technology
Benjamin Petsch, CureVac GmbH, Germany
Title: A novel form of 4-1BB ligand as a potent and safe adjuvant for development of therapeutic cancer vaccines
Rajesh Kumar Sharma, University of Louisville, USA
Title: Correct L1 initiation codon generates immunologically reactive virus-like particles of a novel laboratory mouse papillomavirus (MusPV)
Joongho Joh, University of Louisville, USA

Coffee Break @ Atrium

Title: The T-body approach combining antibody specificity with T cell activity for adoptive vaccination of cancer
Zelig Eshhar, The Weizmann Institute of Science, Israel
Title: Novel non-pyrogenic hydrophobized norAbuMDP and norAbuGMDP analogues for construction of proteoliposome vaccines
Milan Raska, Palacky University, Czech Republic
Title: The pharmacodynamic study and safety evaluation on tuberculosis DNA vaccines
Xueqiong Wu, Institute for Tuberculosis Research, China
Title: Nanoparticles: The next generation delivery vehicle for DNA vaccines
Muhammad Ali A Shah, Southeast University, China

12:30-12:40 Panel Discussion

Lunch Break @ Atrium

Track 4: Vaccines against Infectious Diseases and Cancers

Session Chair: Haval Shirwan, University of Louisville, USA

Session Introduction

Title: Live attenuated tetravalent dengue virus host range vaccine elicits immune response in African green monkeys
Malcolm Thomas, Arbovax Inc, USA
Title: SA-4-1BBL as a Novel adjuvant for the development of therapeutic vaccines
Haval Shirwan, University of Louisville, USA
Title: Vaccination with an adenoviral vector expressing calreticulin human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice
Jorge G. Gomez-Gutierrez, University of Louisville, USA
Title: Plant-derived biopharmaceuticals: Moving plant-derived antibodies and vaccines towards clinical trials
Rainer Fischer, Fraunhofer IME, Germany
Title: Enhancing the efficacy of conventional BCG vaccine
Zakaria Hmama, University of British Columbia, Canada
Title: Vaginal Epithelial Model for testing effectiveness of vaccines and microbicides against STIs
Alwyn Rapose, Reliant Medical Group, USA

Coffee Break @ Atrium

Title: Potent neutralizing antibodies against CMV infection of both fibroblast and epithelial cell infection induced using a multivalent eVLP vaccine candidate
David E Anderson, VBI Vaccines, USA
Title: Intratumoral heterogeneity and identification of tumor initiating cells (TIC) for cancer vaccination
Saroj Basak, University of California Los Angeles, USA
Title: Development of vero cell-based influenza H5N1 vaccines
Min Shi Lee, National Health Research Institutes, Taiwan
Title: Innovations in advanced cancer therapy: Therapeutic vaccines for chronic treatments
Gisela Gonzalez, Center of Molecular Immunology, Cuba
Title: Your vaccine is served; BON APPETIT: An oral DNA carrying nanovaccine targets APC and eradicates melanoma in mice
Pirouz Daftarian, University of Miami, USA

Panel Discussion

Stardust

Young Research Forum

Session Chair: Peter L Nara, Biological Mimetics Inc., USA
Title: Promising horizons: Physicians as HPV vaccine advocates
Sana Shahram, University of British Columbia, Canada

Title: Production and characterization of monoclonal antibodies to Ebola glycoproteins
Humberto Hernandez, University of Texas Medical Branch, USA
Title: Peptide/IFA emulsions limit tumor-specific CD8+ T cells tumor trafficking
Yared Hailemichael, The UT MD Anderson Cancer Center, USA
Title: Tetravalent protein vaccine against Staphylococcus aureus
Nisha Nair, Amrita Centre for Nanosciences and Molecular Medicine, India
Title: RNAi-based characterisation of tegument annexin as a novel vaccine candidate againt schistosomiasis
Leow Yee, Queensland Institute of Medical Research, Australia
Title: DNA vaccine encoding Hantavirus Gn, targeted to the MHC class II compartment by LAMP, significantly elicits specific immune responses and induces immune protection against Hantavirus challenge in vivo
Dongbo Jiang, The Fourth Military Medical University, P.R.China
Title: Safety and immunogenicity of an inactivated whole-virion chromatographic vaccine with aluminum against influenza Ð (H1N1) pdm09: A randomized, blinded, dose-dependent placebo-controlled clinical study
Kaissar Tabynov, Research Institute for Biological Safety Problems, Kazakhstan
Title: Effectiveness of BCG vaccination in preventing tuberculosis
Ahtisham Ul Haq, Service Institue of Medical Sciences, Pakistan
Title: Immunomodulatory functions of defensins, innate molecules, as mucosal adjuvant with the peptide antigens of HIV-1 at the mucosal surfaces
Teena Mohan, All India Institute of Medical Sciences, India

Panel Discussion
Poster Presentations P-001-P-010 @ Riviera
Poster Presentations P-011-P-020 @ Riviera
Cocktails: Sponsored by **Journal of Clinical & Cellular Immunology @ Atrium**

Day 3

Flamingo Ballroom

Track 5: Manufacturing, Production, and Development of Vaccines
to Track 9: Age-specific Immune Response to Vaccinationv

Session Chair: Pedro Reis, AC Immune, Switzerland

Session Introduction

Title: Challenges and exciting solutions to downstream bioprocessing operations for the manufacturing of therapeutic vaccine candidates
Timothy Lee , Latham Biopharm Group, USA
Title: Development of a broad spectrum vaccine against invasive meningococcal disease
Graham Clarke, ImmunoBiology Ltd, UK
Title: SupraAntigenTM technology platform; Manufacturing and development of vaccines for the treatment of Alzheimer diseasew
Pedro Reis, AC Immune, Switzerland
Title: Immunization in family medicine â€“ experiences from Bosnia and Herzegovina
Zarema Obradovic , University of Sarajevo, Bosnia and Herzegovina
Title: Cost-effectiveness of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in medical setting in a developing country (Mozambique)
Vinod Mrithinjayam, Accenture Management Consulting, India
Title: Cost of illness for cholera in a high risk urban area in Bangladesh: An analysis from the household perspective
Abdur Razzaque Sarker, International Centre for Diarrhoeal Disease Research, Bangladesh

Coffee Break @ Atrium

Title: Immunological pattern of Hepatitis B infection among exposed and nonexposed babies in a PMTCT program in low resource setting: Does every exposed newborn require 200IU of hepatitis B immunoglobulin
Joseph Onakewhor, University of Benin Teaching Hospital, Nigeria
Title: Incorporating of immunization course in pharmacy curriculum in Malaysia
Omer Qutaiba B. Al-lela, International Islamic University Malaysia, Malaysia
Title: The observation of the immunization effect of hepatitis b vaccine to the newborn with HBeAg positive
Zahng Ping, Tianjin Institute of Liver Diseases, China

Panel Discussion

Award Ceremony

Lunch Break @ Atrium